FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023005407> ?p ?o ?g. }

• W3023005407 abstract "De Luna et al1 recently reported a favorable outcome of an acute chest syndrome (ACS) related to a SARS-Cov-2 infection treated with tocilizumab (TCZ), in a 45-year-old male patient with homozygous sickle cell disease (SCD). Following this successful observation, TCZ was administered to a teenage girl with SCD who developed a severe COVID-19 associating ACS and pulmonary embolism. This 16-year-old girl has a severe form of homozygous SCD with bilateral ischemic retinopathy. Given the recurrence of vaso-occlusive crises and abnormal transcranial doppler evaluations, she was treated with exchange transfusions from 5 to 11 years old, switched thereafter for hydroxyurea (22 mg/kg/day), with a favorable clinical outcome on vaso-occlusive events. She had no history of ACS or pulmonary hypertension, and her respiratory function and chest radiography were previously normal. As recommended by the French authorities, because of the COVID-19 outbreak, she was confined to her home with her parents. One week after her parents developed COVID-19 symptoms (cough, fever and anosmia), she presented with an isolated fever treated by acetaminophen (without non-steroidal anti-inflammatory drugs). Seven days later, she developed an ACS characterized by an acute chest pain associated with a respiratory distress syndrome (SpO2 85%, superficial tachypnea 80/min, tachycardia 140/min). Real-time reverse transcription-polymerase chain reaction (RT-PCR) of nasopharyngeal swabs confirmed the SARS-Cov-2 infection. Levels of C-reactive protein (355 mg/L), LDH (446 U/L) and D-dimer (23 611 ng/mL) were increased. Given the tachycardia and elevation of D-dimer in a SCD patient with COVID-19, a pulmonary embolism was suspected, which is assumed to be more frequent in this context. Indeed, the computed tomography pulmonary angiography (CTPA) showed a bilateral pulmonary embolism complicating the ACS, and was compatible with COVID-19 (bilateral consolidations with a halo sign on the right side, Figure S1). The patient was admitted to an intensive care unit (ICU) and required non-invasive ventilation, red blood cell exchange transfusion followed by simple transfusion (hemoglobin nadir 6.4 g/dL), and anticoagulation. Because of the severity of the disease, and based on the experience of COVID-19 in SCD adult patients,1-3 she also received one pulse of intravenous tocilizumab (TCZ, 8 mg/kg).1 Plasma level of Interleukin (IL)-6 was extremely high (629 pg/mL; normal <8.5 pg/mL) and was even higher after TCZ (724 pg/mL), in line with IL-6 receptor blockade. To a much less extent, Tumor Necrosis Factor (TNF)-α level was also elevated (32.5 pg/mL; normal <20 pg/mL); and, on the contrary, IL-1β level was normal. The patient improved rapidly after TCZ treatment. Non-invasive ventilation was stopped 4 days after TCZ, with no oxygen requirement thereafter, allowing the discharge from ICU. She was then referred to a medical unit where CTPA was repeated 5 days after TCZ. A dramatic improvement occurred with a disappearance on the right, and a decrease on the left of both the pulmonary embolism and the consolidation opacities, as previously described by Cellina et al.4 (Figure S1). She was finally discharged from the hospital 11 days after admission, with an oral anticoagulant treatment to be continued for a total of 6 weeks. To our knowledge, this is the first reported use of TCZ in a COVID-19 pediatric SCD patient. A single injection of the treatment was followed by a rapid improvement of the patient's respiratory status, together with a dramatic improvement of CTPA images. The etiology of ACS in children with SCD is often multifactorial, combining increased adhesion of sickle red cells to pulmonary microvasculature, pulmonary fat embolism, infarction, and infection, with an excessive inflammatory lung injury response in the presence of a damaged lung microvasculature. Infections are particularly common in children and frequent cause of ACS. The infectious microorganisms principally involved are Streptococcus pneumoniae, Chlamydia pneumoniae, Mycoplasma pneumoniae, Respiratory Syncytial Virus, Influenza virus (notably the H1N1 strain), and Erythrovirus. Besides, monocyte activation has been reported in SCD and is responsible for an enhanced production of pro-inflammatory cytokines such as IL-6,IL-1β and TNF-α, which contributes to vaso-occlusion by promoting endothelial activation.5 Many cytokines are elevated during steady-state in SCD, and some of them, especially IL-6, are further increased during vaso-occlusive crises. To date, SARS-Cov-2 infection has been reported to cause ACS in four adult patients with SCD.1-3 We recently managed two teenage SCD patients with ACS and COVID-19, including the presented case. Note, COVID-19 is characterized by an inflammatory storm enhanced by T cells and monocytes. Large amounts of IL-6 and TNF-α are found in the plasma of infected patients. Tocilizumab, that targets IL-6 receptors, was suggested to be effective on clinical evolution as well as on immune dysregulation.6 After a single TCZ injection, serum IL-6 level first increases rapidly before decreasing. In the absence of significant clinical improvement with persistence of an elevated IL-6 level, a second and a third dose of TCZ can be administered after 12 and 24-36 hours respectively. A favorable CT evolution has been previously described in an adult patient 7 days after two TCZ injections at 12 hour intervals.4 Cytopenia and increased transaminases have been reported and need to be monitored. No adverse effect of TCZ was observed in our patient. In the context of the COVID-19 outbreak, this diagnosis has to be evoked in case of ACS in patients with SCD, as both ACS and COVID-19 pneumonia may present with similar features. The hyper-inflammatory state caused by the SARS-Cov-2 infection may be enhanced by the pro-inflammatory state of SCD. In such patients, TCZ seems to be safe and effective in adults as well as in children, in association with the usual treatment of severe ACS, including non-invasive ventilation and blood exchange transfusion. The authors wish to thank Pr. Pablo Bartolucci (from the Sickle Cell Referral Center of Henri-Mondor University Hospital in Créteil, France) for his expert advice on this case. The authors declare no potential conflict of interest. This correspondence received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Figure S1. Computed tomography pulmonary angiography performed before (A, B) and 5 days after (C, D) Tocilizumab in a child with sickle cell disease, acute chest syndrome and COVID-19. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W3023005407 created "2020-05-13" @default.
• W3023005407 creator A5007768330 @default.
• W3023005407 creator A5017643713 @default.
• W3023005407 creator A5020347600 @default.
• W3023005407 creator A5040751249 @default.
• W3023005407 creator A5043499138 @default.
• W3023005407 creator A5047812172 @default.
• W3023005407 creator A5066420193 @default.
• W3023005407 creator A5078720700 @default.
• W3023005407 creator A5082779937 @default.
• W3023005407 date "2020-05-16" @default.
• W3023005407 modified "2023-09-30" @default.
• W3023005407 title "Dramatic improvement after tocilizumab of severe <scp>COVID</scp>‐19 in a child with sickle cell disease and acute chest syndrome" @default.
• W3023005407 cites W2794850401 @default.
• W3023005407 cites W3014746175 @default.
• W3023005407 cites W3014803927 @default.
• W3023005407 cites W3014821783 @default.
• W3023005407 cites W3015522797 @default.
• W3023005407 cites W3016222783 @default.
• W3023005407 doi "https://doi.org/10.1002/ajh.25855" @default.
• W3023005407 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7267654" @default.
• W3023005407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32358817" @default.
• W3023005407 hasPublicationYear "2020" @default.
• W3023005407 type Work @default.
• W3023005407 sameAs 3023005407 @default.
• W3023005407 citedByCount "52" @default.
• W3023005407 countsByYear W30230054072020 @default.
• W3023005407 countsByYear W30230054072021 @default.
• W3023005407 countsByYear W30230054072022 @default.
• W3023005407 countsByYear W30230054072023 @default.
• W3023005407 crossrefType "journal-article" @default.
• W3023005407 hasAuthorship W3023005407A5007768330 @default.
• W3023005407 hasAuthorship W3023005407A5017643713 @default.
• W3023005407 hasAuthorship W3023005407A5020347600 @default.
• W3023005407 hasAuthorship W3023005407A5040751249 @default.
• W3023005407 hasAuthorship W3023005407A5043499138 @default.
• W3023005407 hasAuthorship W3023005407A5047812172 @default.
• W3023005407 hasAuthorship W3023005407A5066420193 @default.
• W3023005407 hasAuthorship W3023005407A5078720700 @default.
• W3023005407 hasAuthorship W3023005407A5082779937 @default.
• W3023005407 hasBestOaLocation W30230054071 @default.
• W3023005407 hasConcept C116675565 @default.
• W3023005407 hasConcept C126322002 @default.
• W3023005407 hasConcept C159047783 @default.
• W3023005407 hasConcept C177713679 @default.
• W3023005407 hasConcept C187212893 @default.
• W3023005407 hasConcept C203014093 @default.
• W3023005407 hasConcept C2777178219 @default.
• W3023005407 hasConcept C2778620579 @default.
• W3023005407 hasConcept C2779134260 @default.
• W3023005407 hasConcept C2780976302 @default.
• W3023005407 hasConcept C3006700255 @default.
• W3023005407 hasConcept C3007834351 @default.
• W3023005407 hasConcept C3008058167 @default.
• W3023005407 hasConcept C524204448 @default.
• W3023005407 hasConcept C71924100 @default.
• W3023005407 hasConceptScore W3023005407C116675565 @default.
• W3023005407 hasConceptScore W3023005407C126322002 @default.
• W3023005407 hasConceptScore W3023005407C159047783 @default.
• W3023005407 hasConceptScore W3023005407C177713679 @default.
• W3023005407 hasConceptScore W3023005407C187212893 @default.
• W3023005407 hasConceptScore W3023005407C203014093 @default.
• W3023005407 hasConceptScore W3023005407C2777178219 @default.
• W3023005407 hasConceptScore W3023005407C2778620579 @default.
• W3023005407 hasConceptScore W3023005407C2779134260 @default.
• W3023005407 hasConceptScore W3023005407C2780976302 @default.
• W3023005407 hasConceptScore W3023005407C3006700255 @default.
• W3023005407 hasConceptScore W3023005407C3007834351 @default.
• W3023005407 hasConceptScore W3023005407C3008058167 @default.
• W3023005407 hasConceptScore W3023005407C524204448 @default.
• W3023005407 hasConceptScore W3023005407C71924100 @default.
• W3023005407 hasIssue "8" @default.
• W3023005407 hasLocation W30230054071 @default.
• W3023005407 hasLocation W30230054072 @default.
• W3023005407 hasLocation W30230054073 @default.
• W3023005407 hasLocation W30230054074 @default.
• W3023005407 hasOpenAccess W3023005407 @default.
• W3023005407 hasPrimaryLocation W30230054071 @default.
• W3023005407 hasRelatedWork W3009669391 @default.
• W3023005407 hasRelatedWork W3036314732 @default.
• W3023005407 hasRelatedWork W3046484251 @default.
• W3023005407 hasRelatedWork W3111470595 @default.
• W3023005407 hasRelatedWork W3134057351 @default.
• W3023005407 hasRelatedWork W3164382380 @default.
• W3023005407 hasRelatedWork W3179754497 @default.
• W3023005407 hasRelatedWork W4205317059 @default.
• W3023005407 hasRelatedWork W4206669628 @default.
• W3023005407 hasRelatedWork W4316928760 @default.
• W3023005407 hasVolume "95" @default.
• W3023005407 isParatext "false" @default.
• W3023005407 isRetracted "false" @default.
• W3023005407 magId "3023005407" @default.
• W3023005407 workType "article" @default.